Literature DB >> 18752045

INCENP (inner centromere protein) is overexpressed in high grade non-Hodgkin B-cell lymphomas.

Sotirios Barbanis1, Maria Ioannou, Evangelos Kouvaras, Foteini Karasavvidou, Marianna Nakou, Roidoula Papamichali, George Koukoulis.   

Abstract

Inner centromere protein (INCENP) is a member of the Chromosomal Passenger Complex (CPC), which is a four member protein complex essential for proper completion of mitosis and cell division (cytokinesis). Inappropriate chromosomal segregation and cytokinesis due to deregulated expression of chromosome passenger proteins may lead to aneuploidy and cancer including lymphomas. According to our knowledge this is the first study investigating immunohistochemical expression of INCENP in lymphoma cases and cancer tissues in general. Our purpose was to characterize the expression of INCENP in cases of non-Hodgkin B-cell lymphomas, to compare the immunoreactivity between low and high grades and to evaluate the correlation between INCENP and MIB-1 labeling indices. We examined INCENP and MIB-1 immunoreactivity in paraffin sections of 55 samples of non-Hodgkin B-cell lymphomas, obtained from 55 patients, 31 men and 24 women. Thirty were of high grade and 25 were of low grade. Our results showed significantly higher nuclear immunohistochemical expression of INCENP in high grade B-cell lymphomas versus low grade ones. Also INCENP expression was significantly correlated with MIB-1 labeling index. Taken together our results point to a possible association between increased INCENP immunostaining and B-cell lymphoma aggressiveness and also stress the need for further investigating the expression of INCENP and other mitotic regulatory proteins in lymphomas and other malignant neoplasms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752045     DOI: 10.1007/s12253-008-9094-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  28 in total

Review 1.  A roar for INCENP.

Authors:  S Greaves
Journal:  Nat Cell Biol       Date:  2001-01       Impact factor: 28.824

2.  INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis.

Authors:  S P Wheatley; A Carvalho; P Vagnarelli; W C Earnshaw
Journal:  Curr Biol       Date:  2001-06-05       Impact factor: 10.834

3.  INCENP at the kinase crossroads.

Authors:  Mar Carmena; William C Earnshaw
Journal:  Nat Cell Biol       Date:  2006-02       Impact factor: 28.824

4.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Authors:  T P Miller; T M Grogan; S Dahlberg; C M Spier; R M Braziel; P M Banks; K Foucar; C R Kjeldsberg; N Levy; B N Nathwani
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

5.  Mechanism of Aurora B activation by INCENP and inhibition by hesperadin.

Authors:  Fabio Sessa; Marina Mapelli; Claudio Ciferri; Cataldo Tarricone; Liliana B Areces; Thomas R Schneider; P Todd Stukenberg; Andrea Musacchio
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

6.  Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells.

Authors:  R R Adams; D M Eckley; P Vagnarelli; S P Wheatley; D L Gerloff; A M Mackay; P A Svingen; S H Kaufmann; W C Earnshaw
Journal:  Chromosoma       Date:  2001-05       Impact factor: 4.316

Review 7.  Survivin in apoptosis control and cell cycle regulation in cancer.

Authors:  Dario C Altieri
Journal:  Prog Cell Cycle Res       Date:  2003

8.  A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.

Authors:  Tryfonia Mainou-Fowler; Lynn Marie Overman; Helen Dignum; Katrina Wood; Stephen Crosier; Brian Angus; Stephen John Proctor; John J Anderson
Journal:  Int J Oncol       Date:  2008-01       Impact factor: 5.650

Review 9.  Chromosomal passengers: conducting cell division.

Authors:  Sandrine Ruchaud; Mar Carmena; William C Earnshaw
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

10.  Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation.

Authors:  Rosanna Sorrentino; Silvana Libertini; Pier Lorenzo Pallante; Giancarlo Troncone; Lucio Palombini; Vassilios Bavetsias; Daniela Spalletti-Cernia; Paolo Laccetti; Spiros Linardopoulos; Paolo Chieffi; Alfredo Fusco; Giuseppe Portella
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

View more
  5 in total

1.  Targeting the Chromosomal Passenger Complex Subunit INCENP Induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.

Authors:  Ming Sun; Veronica Veschi; Sukriti Bagchi; Man Xu; Arnulfo Mendoza; Zhihui Liu; Carol J Thiele
Journal:  Cancer Res       Date:  2019-08-15       Impact factor: 12.701

2.  Aurora B kinase in Hodgkin lymphoma: immunohistochemical pattern of expression in neoplastic Hodgkin and Reed-Sternberg cells.

Authors:  M Ioannou; E Kouvaras; E Stathakis; M Samara; G K Koukoulis
Journal:  J Mol Histol       Date:  2013-12-24       Impact factor: 2.611

3.  PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP.

Authors:  Xiaolan Deng; Gottfried Von Keudell; Takehiro Suzuki; Naoshi Dohmae; Makoto Nakakido; Lianhua Piao; Yuichiro Yoshioka; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Oncotarget       Date:  2015-11-03

4.  Upregulation of CENP-H in tongue cancer correlates with poor prognosis and progression.

Authors:  Wen-Ting Liao; Chun-Ping Yu; Dong-Hui Wu; Ling Zhang; Li-Hua Xu; Gui-Xiang Weng; Mu-Sheng Zeng; Li-Bing Song; Jin-Song Li
Journal:  J Exp Clin Cancer Res       Date:  2009-06-05

5.  Functional SNPs of INCENP Affect Semen Quality by Alternative Splicing Mode and Binding Affinity with the Target Bta-miR-378 in Chinese Holstein Bulls.

Authors:  Juan Liu; Yan Sun; Chunhong Yang; Yan Zhang; Qiang Jiang; Jinming Huang; Zhihua Ju; Xiuge Wang; Jifeng Zhong; Changfa Wang
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.